Laboratory Corporation of America Holdings (NYSE:LH) Receives Media Sentiment Rating of 0.14

News coverage about Laboratory Corporation of America Holdings (NYSE:LH) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Laboratory Corporation of America Holdings earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.9472101630526 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Laboratory Corporation of America Holdings (NYSE LH) traded down 0.12% during midday trading on Friday, hitting $156.21. 441,945 shares of the company traded hands. The firm has a market capitalization of $15.90 billion, a PE ratio of 21.88 and a beta of 0.94. The stock’s 50-day moving average is $155.35 and its 200-day moving average is $144.27. Laboratory Corporation of America Holdings has a 12-month low of $119.51 and a 12-month high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.40 by $0.07. The firm had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.36 earnings per share. Analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 EPS for the current fiscal year.

LH has been the topic of several research analyst reports. Zacks Investment Research cut shares of Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, April 19th. Jefferies Group LLC lowered their price target on shares of Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating on the stock in a report on Friday, April 28th. Credit Suisse Group restated a “buy” rating and set a $146.00 price target on shares of Laboratory Corporation of America Holdings in a report on Sunday, May 28th. ValuEngine cut shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Saturday, June 3rd. Finally, BidaskClub cut shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $159.00.

COPYRIGHT VIOLATION WARNING: “Laboratory Corporation of America Holdings (NYSE:LH) Receives Media Sentiment Rating of 0.14” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.thestockobserver.com/2017/08/12/laboratory-corporation-of-america-holdings-nyselh-given-news-impact-score-of-0-14-updated-updated.html.

In other news, insider Lisa J. Uthgenannt sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $160.00, for a total transaction of $800,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Glenn A. Eisenberg sold 5,968 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $159.46, for a total transaction of $951,657.28. Following the sale, the chief financial officer now owns 18,122 shares of the company’s stock, valued at approximately $2,889,734.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,581 shares of company stock valued at $2,256,899. Corporate insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply